Radioimmunoassays (RIA) have been shown to be unreliable in measuring serum thyroglobulin levels in patients with anti thyroglobulin antibodies. The aim of this study was twofold. Firstly to compare the abilities of two immunoradiometric assays (IRMA), one commercially available, the other an 'in house' assay, with a conventional RIA. In addition the prognostic value of serum thyroglobulin levels in patients likely to relapse following a course of antithyroid drugs for Graves' disease was examined.
Thyroglobulin, a large glycosylated protein of molecular weight 660 000 dalton, is synthesised by the thyroid cell and secreted into the follicular lumen.
Levels of serum thyroglobulin are low in normal subjects. They are however elevated in patients with Graves' disease or in the presence of metastases in patients with thyroid cancer. 1-5 The latter is the most established clinical application for serum thyroglobulin measurements at present. However, thyroglobulin levels have also been measured in Graves' disease patients following a course of antithyroid drugs with the aim of identifying patients likely to relapse. These studies have met with varying degrees of sue-cesS. 3 • 6 ,7 In the majority of previous studies thyroglobulin levels were measured using a double antibody RIA.II This method has, however, proved unreliable in the presence of anti thyroglobulin antibodies which are known to occur in 20-30% of Graves' disease patients." This has resulted in patients with antithyroglobulin antibodies, as detected by haemagglutination or other techniques, being excluded from many studies. However a positive result for anti thyroglobulin antibodies using a haem agglutination technique only occurs when the titre is relatively high. Therefore sera that are negative for antithyroglobulin antibodies by this method may still have antibodies in sufficient titre to interfere in an RIA for serum thyroglobulin. Interference by anti thyroglobulin antibodies can be overcome either by using a second antibody (anti-rabbit IgG) which has very little cross reaction with human IgG9or by using a modified RIA. 10 These steps are time consuming and, as in the case of Black et al.,9 the antibody may be difficult to obtain.
The aim of this study was to compare the ability of two IRMA assays (one obtained from Medgenix Ltd, Brussels, Belgium, and the other an 'in house' assay) and a conventional RIA to measure thyroglobulin levels in Graves' patients. The solid phase sandwich technique used in the IRMA should exclude the false positive results caused by anti thyroglobulin antibodies in RIA. In addition the prognostic value of serum thyroglobulin levels in identifying patients likely to relapse following a course of antithyroid drugs was also determined.
Methods

COMMERCIALL Y AVAILABLE IRMA
This IRMA kit (Medgenix Ltd) uses a two step immunoradiometric solid phase method where thyroglobulin in the standards or samples binds to antibody fixed on the inside of the tube. An excess of monoclonal antibody to thyroglobulin is added and after incubation the medium is aspirated and the radioactivity bound to the tube is directly correlated to the amount of thyroglobulin in the sample. The thyroglobulin concentration in the sample is determined from a standard curve. Values in normal individuals ranged from undetectable to 70 ng/ml.,
IN HOUSE IRMA
Thyroglobulin standard
Thyroglobulin was prepared from thyroid glands obtained at autopsy from individuals with no apparent thyroid disease according to the method of van Herle et al,"
using a double antibody radioimmunoassay according to the method of Van Herle et al," The intra assay CV was 3·5% at 0 ngjmL and 12% at 1000 ngjmL. The interassay CV was 7·7% and 14.7% respectively. In normal individuals values ranged from 0 to 60 ngjmL. 
Radiolabelled thyroglobulin
An 12ll-labelled monoclonal antibody to human thyroglobulin was supplied by Medgenix Ltd.
RADIOIMMUNOASSA Y
Serum thyroglobulin levels were measured by
Assay protocol
The assay used was a modification of that by Bayer et aU Wells of a micro titre plate (Dynatech Ltd, Billingshurst, Sussex, UK) were coated with the sheep anti-human thyroglobulin preparation (20 JlgjmL) in 0·05 M to carbonate bicarbonate buffer for 4 h at 37°C. The solution was then aspirated, the cups washed three times with phosphate-buffered saline (PBS), then filled with normal rabbit serum (NRS) and incubated for 5 min at 37°C to minimise non specific binding. Thyroglobulin standards or patients' sera (200 JlI) were added and incubated for a further 3 h at 37°C. The contents were then aspirated, the wells washed and 1211 antibody (37 JlBqj200 JlL) added to the wells. Two additional tubes for total counts were included. The plates were then incubated for 24 h at room temperature. The contents were then aspirated, washed and the radioactivity in each well determined by counting in a gamma counter. The concentration of unknown samples is determined from a standard curve. In normal individuals values ranged from 0 to 70 ngjmL.
Sheep anti-human thyroglobulin-Igti for coating
Commercially obtained sheep anti-human thyroglobulin (lCN biomedicals, High Wycombe, Bucks, UK) was applied to DEAE Sephadex A 50 and the IgG fraction eluted with 0·01 M sodium I phosphate buffer according to the method of Baumstark et al, 12 The antithyroglobulin-lgG fraction was then affinity purified by using a cyanogen bromide (CN-Br) activated sepharose 4B column. After washing at low pH (2-3) to remove additives the gel was coupled to purified thyroglobulin by mixing for 2 h at 37°C. Unbound thyroglobulin was removed by washing. The antithyrogiobulin-lgG fraction was then applied to the column and subsequently eluted with 0·2 M glycine HCI (pH 2) into I mL phosphate buffer (pH 7'3).
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added to each well. Incubation at room temperature for 18-24 h gave optimal binding (Fig. 3) . 
1000
Precision profile A precision profile was calculated for the 'in house' IRMA according to the method of Rodgers." The results obtained (Table I) 
Patients
Serum thyroglobulin levels were measured in 42 Graves' disease patients prior to and on completion of a 12 month course of antithyroid drugs. The patients were selected so that 22 were positive for antithyroglobulin antibodies (Thymune T, Wellcome Ltd, Beckenham, Kent, UK). All patients were followed for a further 12 months 0·07  0·20  0·35  SI  10  5·6  0·07  0·13  0·53  5·3  S2  50  10·3  0·23  0·097  2·37  4·7  S3  100  14·4  0·33  0·053  6·22  6·2  S4  250  21·0  0·44  0·031  14·19  5·6  S5  500  27·0  0·49  0·017  28·80  5·7  S6  1000  34·0  0·58  0·014  41·40  4·1 after the end of therapy and during this time 22 relapsed. The mean period of time taken for patients to relapse was 4·6 ± 2·6 months.
those who remained in remission, regardless of the method used.
Results
Serum thyroglobulin levels were measured at presentation by RIA, IRMA (Medgenix Ltd) and by our 'in house' IRMA ( Fig. 4) . Thyroglobulin levelswere elevated in many patients at this stage. Mean values for the three methods did not differ significantly (195,1 ±253 [RIA] vs 184±272 [Medgenix IRMA] vs 183± 281 ['in house' IRMA] ng/ml.), Correlation coefficients for the various assays showed that while IRMA and RIA methods correlated weU for patients negative for anti thyroglobulin antibodies, this was not so for antibody positive patients ( Table 2 ). This would confirm previous reports of antibody interference in RIA. Results obtained between commercial and 'in house' IRMA methods correlated weU. Thyroglobulin levelswere measured by IRMA, either Medegenix or 'in house', foUowing a 12 month course of antithyroid drugs (Fig. 5 ). While levels had faUen in both patient groups with treatment, the faU was not statisticaUy significant (184±272 vs 123±233 [Medgenix IRMA]; 183±281 vs 125±220['in house' IRMA] ng/ml.). No significant differences in mean thyroglobulin levelswere found between those who relapsed and 
Discussion
Since the introduction of an assay to measure serum thyroglobulin, II there have been many reports concerning the problems in using RIA methods when antithyroglobulin antibodies are present. As similar interference was found to occur in an ELISA assay," this study aimed to compare an 'in house' IRMA, a recent commer-ciaUy available IRMA and a conventional RIA. The results obtained showed good correlation for antibody negative patients between all three assays. However, the RIA method correlated poorly with both IRMA methods for antithyroglobulin positive patients. This confirms earlier reports of falsely high and low thyroglobulin results in the presence of anti thyroglobulin antibodies.4.lo.II,14 The 'in house' and commercially available IRMA methods used tubes pre-eoated with an anti thyroglobulin preparation. The addition of serum positive for anti thyroglobulin antibodies showed that these did not bind to the tubes and subsequent washing steps removed them from the assay. Bayer did not interfere in the assay, thyroglobulin levels were found to be falsely reduced in some samples. This was thought to bedue to the thyroglobulin in the thyroglobulin-antithyroglobulin complexes binding less than free thyroglobulin. This problem appeared to be minimal in the IRMA methods used in this study. The satisfactory results obtained may be due to the use of a high affinity monoclonal rather than a polyclonal antibody. Previous studies have considered the clinical value of measuring serum thyroglobulin levels. found to be within the normal range in patients remaining in remission for more than 7 months. In patients who ultimately relapsed, a rise in serum thyroglobulin levels, which preceeded the rise in serum Tvlevels, was observed. This led the authors to conclude that a rise in serum thyroglobulin may be a good predictor of thyroid stimulation in the early phase of Graves' disease. Studies by Izumi et al," and Gardner et al. l ? showed that while mean thyroglobulin levels declined significantly in patients who remained in remission for a substantial period of time, prediction of relapse in an individual case was less certain.
In the present study thyroglobulin levels were within the normal range in many patients who relapsed as well as those who remained in remission, while elevated thyroglobulin levels were found in a proportion of patients in both groups. These data suggest that serum thyroglobulin levels are a poor prognostic indicator. Data obtained previously for our patients, at the end of a 12 month course of antithyroid drugs, showed that thyrotropin receptor antibody levels could distinguish, in 90% of patients, between those who relapsed and those who remained in remission."
In conclusion, it would appear that an IRMA can reliably be used to measure serum thyroglo-bulin levels irrespective of whether or not the patients are positive for anti thyroglobulin antibodies.
